Loading...
XTAE
CBI
Market cap12mUSD
Oct 09, Last price  
23.80ILS
1D
-2.46%
1Q
-12.50%
Jan 2017
-90.10%
IPO
-97.67%
Name

Clal Biotechnology Industries Ltd

Chart & performance

D1W1MN
XTAE:CBI chart
P/E
—
P/S
44.71
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.55%
Rev. gr., 5y
32.30%
Revenues
835k
+92.84%
2,062,0001,339,0003,182,0004,745,0003,545,0009,067,0007,671,0003,452,00023,899,00025,417,00024,183,00043,461,00012,767,000113,293,000206,000224,000370,000104,000433,000835,000
Net income
-13m
L-78.67%
-15,442,000-44,557,000-83,042,00065,425,000350,868,00087,333,000-93,554,000-151,602,000-367,635,000-118,462,000-213,820,000-27,893,000-44,942,000-154,112,000109,027,000-89,583,000-61,740,000-31,051,000-62,456,000-13,319,000
CFO
-4m
L-37.14%
-23,549,000-47,049,000-52,415,000-86,860,000-111,926,000-102,451,000-81,222,000-148,976,000-115,952,000-146,999,000-112,633,000-91,405,000-86,981,00027,029,000-33,226,000-41,327,000-59,037,000-8,513,000-6,478,000-4,072,000
Dividend
Mar 29, 202122.3722 ILS/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Clal Biotechnology Industries Ltd. (CBI) operates as a venture capital and private equity firm, primarily funding innovative companies within the life sciences, medical device, biopharmaceutical, and broader biotechnology sectors. The firm is adept at investing across a comprehensive spectrum of development stages, ranging from initial incubation, seed, and startup phases, through early, emerging, mid, and late-stage ventures, including pre-clinical development, PIPEs, and growth capital financing. CBI strategically targets companies based in the United States and Israel, typically deploying between $0.5 million and $10 million into each investment. It frequently assumes the role of a lead investor and a significant shareholder, often securing a board seat within its portfolio companies. Established in July 1998, CBI utilizes the personal capital of its management team for its investments. Its primary base is in Tel Aviv, Israel, complemented by an additional office in Cambridge, Massachusetts. The firm formerly functioned as a subsidiary of Clal Industries and Investments Ltd.

Key people

Avraham Fischer
Chairman of the Board · since 2003
Ofer Gonen
Chief Executive Officer · since 2017
Julian Adams
President, Chief Scientific Officer · since 2017
Assaf Segal
Vice President - Finance · since 2015
Ofer Goldberg
Vice President · since 2003
Orit Lidor
Vice President, General Counsel · since 2011
Tomer Babai
Director · since 2017
Gavriel Barabash
Director · since 2003
Isaac Kohlberg
Director · since 2015
Nofar Malovani
Director · since 2017
Aharon Schwartz
Director · since 2005
Shmuel Rubinstein
External Director · since 2011
Yuval Yanai
External Director · since 2015
URL
https://www.cbi.co.il/
IPO date
May 30, 2007
Employees
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT